Cordis Corporation

Johnson & Johnson Consumer Inc.

Cardinal Health Switzerland 515 Gmbh

Other

Mcneil-ppc, Inc.

Johnson & Johnson Consumer Companies, Inc.

Cardinal Health 529, LLC

Qiang Zhang

Murty N. Vyakarnam

Robert Burgermeister

Vipul Dave

Vipul Bhupendra Dave

Gerard P McNally

Thomas Palermo

Robert Falotico

Jonathon Zhong Zhao

Joseph Henry Contiliano

David W Overaker

Gregory E Koll

Theodore L Parker

Harold D Ochs

Thai Minh Nguyen

Chao Chin-Chen

Chengxue Li

Anurag Pandey

Thai M Nguyen

Thomas J Palermo

David Christopher Majercak

Ying Sun

Yufu Li

Elvin R Lukenbach

Mark B Roller

Iksoo Chun

Pallassana V Narayanan

Ryan R Donovan

Christopher Szymczak

Howard Scalzo

Mark David Saindon

Jerome A Fischer

Ramesh Marrey

Jacob Leidner

George Landau

Chao-Chin Chen

Ram L Kataria

Stephen Ulrich

Jerry W Fisher

Diana L Friscia

Carol A Duden

David Cook

Thai Nguyen

Brian R White

John Chodzko

David B Cochran

Murty N Vyakamam

Christopher E Szymczak

Randy-David Bruce Grishaber

Stephen Johnstone

Gerard P Mcnally

Eileen Peng

Murty N Vyakarnam

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

Soft chewable dosage form

Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Liquid compositions

Liquid compositions for treating cough or cold symptoms

In one aspect the present invention features process for making a tablet comprising at least one pharmaceutically active agent, said method comprising the step of applying radiofrequency energy to a powder blend to sinter said powder blend into said tablet, wherein said powder blend comprises lossy coated particles and said at least one pharmaceutically active agent, wherein said lossy coated particles comprises a substrate that is at least partially coated with a lossy coating comprising at least one activator, wherein said substrate has a Q value of greater than 100 and said activator has a Q value of less than 75.

Process for making tablet using radiofrequency and lossy coated particles

Biocompatible materials may be configured into any number of implantable medical devices including intraluminal stents. The biocompatible material may comprise metallic and non-metallic materials in hybrid structures. In one such structure, a device may be fabricated with one or more elements having an inner metallic frame that is not degradable with an outer shell formed from a polymeric material that is biodegradable by extrusion blow molding. Additionally, therapeutic agents may be incorporated into the microstructure or the bulk material.

Bioabsorbable polymer, non-bioabsorbable metal composite stents

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics. The stent has a plurality of hoop components interconnected by a plurality of flexible connectors. The hoop components are formed as a continuous series of substantially longitudinally or axially oriented radial strut members and alternating substantially circumferentially oriented radial arc members. The geometry of the struts and arcs is such that when the stent is expanded, it has very high strains within a relatively small region. This strain localization results in what is often referred to as 'hinging', where the hinge is the small region within which the strains are very high.

Balloon expandable bioabsorbable drug eluting stent

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics. The stent has a plurality of hoop components interconnected by at least one flexible connector. The hoop components are formed as a continuous series of alternating substantially longitudinally oriented strut members and connector junction struts, whereas the longitudinal strut is connected to the connector junction strut by alternating substantially circumferentially oriented arc members.

Balloon expandable bioabsorbable drug eluting flexible stent

A biocompatible material may be configured into any number of implantable medical devices including a vascular closure device. The vascular closure device includes a fibrous structure formed from at least one randomly oriented fiber, the randomly oriented fiber comprising at least one polymer, and at least one agent, in therapeutic dosage, incorporated into at least one of the fibrous structure and the at least one randomly oriented fiber.

Vascular closure device

A method of making a biocompatible, implantable medical device, including a vascular closure device is disclosed. The method includes forming a biocompatible polymer into at least one fiber and randomly orienting the at least one fiber into a fibrous structure having at least one interstitial spaces. Polymeric materials may be utilized to fabricate any of these devices. The polymeric materials may include additives such as drugs or other bioactive agents as well as antibacterial agents. In such instances, at least one agent, in therapeutic dosage, is incorporated into at least one of the fibrous structure and the at least one fiber.

Method of making a vascular closure device

The present invention relates to a process for reducing solvent contents in drug-containing polymeric compositions. Specifically, the solvent contents in the drug-containing polymeric compositions are first reduced by one or more conventional drying methods, to a range from about 0.5 wt % to about 10 wt % of the total weight of the polymeric composition. Subsequently, the drug-containing polymeric compositions are further treated by one or more low temperature (i.e., having processing temperatures of less than 60&#xb0; C.) drying methods for further reduction of the solvent content to less than 10,000 ppm.

Low temperature drying methods for forming drug-containing polymeric compositions

An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, masking and de-masking processes may be utilized.

Adhesion promoting temporary mask for coated surfaces

The present invention provides a porous structure that works very effectively to seal a puncture site with optimum porosity, absorbent capacity and perfect anatomical fit. The plug density and other fiber properties/geometry (total denier; number of filaments; etc) have provided an efficient structure that allows instantaneous absorption of blood during deployment. The final size of the plug with absorbed fluids provides an anatomical fit and seals the puncture site within few minutes after deployment.

A medical device has a structure made of a first biodegradable and/or bioabsorbable material and a second biodegradable and/or bioabsorbable material encapsulating a degradation additive incorporated into the first biodegradable and/or bioabsorbable material. The second biodegradable and/or bioabsorbable material has a degradation rate that is faster than the degradation rate of the first biodegradable and/or bioabsorbable material such that the structure experiences a period of accelerated degradation upon release of the degradation additive following sufficient degradation of the second biodegradable and/or bioabsorbable material.

Bioabsorbable device having composite structure for accelerating degradation

Growing community of inventors

Belle Mead, NJ, United States of America

Vipul Bhupendra Dave